Press

Filament Health Announces Clinical Trial Approval in Partnership With Psychiatric Centre Copenhagen

Jan 20 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced the approval of a clinical trial in partnership with Psychiatric Centre Copenhagen, Denmark’s largest psychiatric centre known for being at the forefront of new treatment options that stem from recognized research. The trial, led by PhD student Mathias Ebbesen…

Mydecine Innovation Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

Jan 20 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: ONFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement with a third-party…

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Jan 20 • 4 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF | CSE: RVV | FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that it has submitted the updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include the rationale for the proposed…

Numinus Wellness Inc. Reports Q1 2023 Results

Jan 20 • 7 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended November 30, 2022 (“Q1 2023”). “During the first quarter of fiscal 2023, we successfully implemented several initiatives to increase access to psychedelic and ketamine-assisted therapy. We believe…

Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers

Jan 18 • 6 min read

Core One Labs Inc. (CSE:COOL | OTCQB:CLABF | Frankfurt:LD6 | WKN: A3CSSU), is pleased to announce that it has acquired GMP Drug Inc., an arms-length privately held company that operates through a Good Manufacturing Practices facility owned by a third-party located in Ontario, Canada. The Acquisition will lay the path for the Company to become a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435